Ireland: Biosynth Carbosynth expands IVD offering with acquisition of Aalto Bio Reagents

KKR-backed Biosynth Carbosynth, a materials supplier to the life science industry, has acquired Ireland-based Aalto Bio Reagents is a global provider of proteins, antigens, HIV antibodies and disease state human plasma to the in-vitro diagnostic (IVD) industry.

Financial terms were not disclosed.

The acquisition broadens Switzerland-based Biosynth’s capabilities and offering to the IVD industry. Aalto’s product portfolio includes a range of proteins, antigens, antibodies, disease state human plasma and biospecimens used by the leading diagnostics and vaccine development companies around the world working on emerging diseases and disease variants.

“This acquisition marks the next phase of our ambitious journey to become a leading global supplier and partner to the biopharma and diagnostics industries,” said Dr Urs Spitz, CEO and president of Biosynth. “It allows us to offer an expanded range of products to our IVD customers including complex biochemicals, peptides and biological materials.”

In November 2021, KKR agreed to acquire Biosynth Carbosynth from Munich-based investor, Armira, and CEO Spitz.